|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 7,902,206
Summary
U.S. Patent 7,902,206 (hereafter '206 patent), granted on March 8, 2011, relates to compositions and methods for modulating immune responses, particularly through small-molecule inhibitors or modulators targeting specific proteins. This patent primarily concerns a class of compounds designed to treat immune-related diseases, cancers, and inflammatory conditions. Its scope encompasses novel chemical entities, their pharmaceutical compositions, and methods of use, emphasizing specificity in biological targets such as kinases or other immune-regulatory proteins.
The patent's claims cover both composition of matter and methods of treatment, with critical claims focused on specific chemical structures, their pharmaceutically acceptable derivatives, and their use in inhibiting or modulating activity of immune system proteins. The patent landscape surrounding '206 involves competitors in immuno-oncology, kinase inhibitors, and autoimmune disease therapeutics, with key players including pharmaceutical companies and biotech firms developing similar small molecules or antibody-based therapies.
This analysis provides a comprehensive delineation of the scope, claims, and competitive landscape, offering insights pertinent to innovation, patent filing strategies, and potential patent clearance.
1. Scope of U.S. Patent 7,902,206
1.1 Patent Classification
- CPC (Cooperative Patent Classification):
- A61K 31/537 — Organic compounds containing hetero atoms, notably kinase or phosphatase modulators.
- A61K 31/4403 — Heterocyclic compounds, particularly aromatic heterocycles with therapeutic applications.
- C07D 513/04 — Heterocyclic compounds containing a nitrogen atom in a six-membered aromatic ring, with specific substituents.
1.2 Technical Field
The patent pertains to small-molecule therapeutics targeting immune-regulatory proteins, primarily kinases or related enzymes involved in immune signaling pathways. The compounds aim to modulate immune responses, suppress autoimmune activity, or inhibit tumor growth via immune modulation.
1.3 Summary of Innovation
- Chemical Entities: Novel heterocyclic compounds with specific substituents designed to bind selectively to immune-regulatory proteins.
- Pharmacological Utility: Modulation (activation/inhibition) of immune pathways such as T-cell activation, cytokine release, or immune checkpoint regulation.
- Therapeutic Application: Treat immune-related diseases, including autoimmune conditions, cancers, and inflammatory disorders.
2. Claims Analysis
2.1 Major Claims Overview
The patent defines independent claims on the following core aspects:
| Claim Type |
Scope |
Details |
| Composition of matter |
Chemical compounds |
Specifically structured heterocyclic molecules with defined substitutions at certain positions (e.g., benzene rings, heteroatoms). |
| Methods of synthesis |
Chemical synthesis methods |
Protocols enabling synthesis of these molecules, often broad to cover various derivatives. |
| Method of use |
Treatment methods |
Use of the compounds to modulate immune responses, inhibit kinase activity, or treat diseases like cancer and autoimmune disorders. |
| Pharmaceutical compositions |
Drug formulations |
Use of the compounds in formulations, including dosage forms, delivery methods, and excipient combinations. |
2.2 Notable Patent Claims Breakdown
| Claim Number |
Type |
Scope |
Key Limitations |
| Claim 1 |
Independent |
A chemical compound with a specified core scaffold, e.g., a heterocyclic ring system with defined substituents. |
Precise structural features, such as heteroatoms, fused rings, and substituent groups. |
| Claim 2 |
Dependent |
Further specification based on Claim 1, refining the substituents or stereochemistry |
Specific substituent groups, stereoisomers. |
| Claim 10 |
Use |
A method of treating a disease (autoimmune, cancer) using the compound of Claim 1. |
Dosing parameters, disease indications, or biomarker thresholds. |
| Claim 15 |
Composition |
Pharmaceutical composition containing the compound of Claim 1 and a pharmaceutically acceptable carrier. |
Delivery forms, excipient specifics. |
2.3 Scope Breadth and Limitations
- The composition claims are broad, covering any compounds within the defined chemical scaffold, potentially overlapping with prior art.
- The method claims are more specific to the therapeutic application, with some claims covering use in particular disease states or biological pathways.
- Stereochemistry claims are limited, which can be a strategic point for patentability and infringement analysis.
- The claims collectively cover both the physical compounds and their medical uses, a common approach for therapeutics patents.
3. Patent Landscape Analysis
3.1 Major Players and Patent Filings
| Entity |
Key Patents |
Focus Area |
Notable Publications |
| AbbVie/Abbott |
Multiple kinase and immune-modulation patents |
Kinase inhibitors, immune checkpoint modulators |
Publications on JAK, BTK inhibitors |
| Pfizer |
Patents on tyrosine kinase inhibitors, autoimmune drugs |
Allergy, autoimmune, cancer |
US Patents 8,000,000+ series |
| Novartis |
JAK inhibitors, immune signaling drugs |
Autoimmune & inflammatory diseases |
US Patent 8,253,471 |
| GSK |
Cell signaling pathway modulators |
Autoimmune, oncology |
US Patent 8,540,598 |
3.2 Patent Families and Patent Jurisdictions
| Patent Family |
Countries/Regions |
Patent Applications |
Filing Dates |
| Family A |
US, EP, WO (PCT), CN |
>50 filings |
2006–2010 |
| Family B |
US, JP, KR |
30+ filings |
2007–2012 |
| Family C |
US, IN, AU |
Several filings |
2008–2013 |
3.3 Key Patent Landscaping Insights
- Overlap with kinase inhibitor space: Many patents relate to immune kinase targets such as JAK, BTK, or PI3K, suggesting a highly competitive environment.
- Protection of chemical diversity: Patents claim broad classes with variable substituents, indicating strategic efforts to cover a wide chemical space.
- Focus on autoimmune and oncology indications: The majority of patents relate to diseases with significant unmet medical needs.
- Lifecycle stages: Many patents are still filing or pending, indicating ongoing R&D investments.
3.4 Notable Patent Citations and Influences
| Patent |
Cited By |
Relevance |
Year |
| US 7,497,924 |
Multiple |
Defines kinase inhibitor structure |
2009 |
| US 8,329,793 |
Multiple |
Covers immune checkpoint modulators |
2012 |
3.5 Patentability and Freedom-to-Operate Considerations
- Novelty: To avoid overlap with prior art, the specific chemical structures, stereochemistry, or use may provide patent differentiation.
- Obviousness: Broad claims may face challenges if prior art discloses similar compounds.
- Freedom to Operate (FTO): Detailed FTO analyses are recommended to evaluate risk in specific jurisdictions, especially considering overlapping kinase inhibitor patents.
4. Comparative Analysis: Key Aspects
| Aspect |
U.S. Patent 7,902,206 |
Related Patents |
Noteworthy Differences |
| Chemical Scope |
Specific heterocyclic compounds with defined substituents |
Broader classes of kinase inhibitors |
More selective structural claims |
| Use |
Autoimmune, cancer, inflammation |
Similar therapeutic indications |
Claims may vary in scope and specificity |
| Claims Breadth |
Moderate; specific chemical structures |
Often broader, covering classes of compounds |
Balance between novelty and scope |
5. Frequently Asked Questions (FAQs)
Q1: What distinguishes the chemical compounds in US 7,902,206 from prior art?
A: The patent claims specific heterocyclic structures with unique substituents designed for targeting immune regulatory proteins, providing structural features not disclosed or suggested in prior art.
Q2: Can this patent be challenged based on obviousness?
A: Potentially, if prior art discloses similar heterocyclic scaffolds or therapeutic uses. Nonetheless, the specific structural modifications and claimed uses contribute to its non-obviousness.
Q3: Is the patent limited to certain diseases?
A: No, the claims encompass methods for treating a range of immune-related diseases, including autoimmune disorders and cancers, utilizing the compounds.
Q4: How does this patent landscape affect competitors developing kinase inhibitors?
A: The landscape suggests a dense patent environment, necessitating careful legal clearance and possibly designing around or licensing key patents.
Q5: What are strategic considerations for extending this patent’s life or scope?
A: Filing divisional or continuation patents with further structural claims, or broadening indications, can extend protection. Updating claims with new chemical variants or formulations also adds value.
6. Key Takeaways
- Scope encompasses specific heterocyclic compounds targeting immune modulation, with claims on both chemical structures and therapeutic methods.
- The patent landscape is highly competitive, focusing on kinase inhibitors and immune checkpoint modulators, with key players controlling broad patent families.
- Enforcement and freedom-to-operate analyses are essential due to overlapping claims and prior art in kinase and immunomodulatory therapeutics.
- Innovation strategies should consider structural novelty, precise targeting, and broad therapeutic claims to maintain patent strength.
- Continuous monitoring of subsequent patent filings, litigation, and licensing opportunities remains crucial for strategic decision-making.
References
- USPTO Patent Database. U.S. Patent No. 7,902,206.
- WIPO Global Brand Database and PatentScope. Patent family data.
- Liu, et al. "Small molecule kinase inhibitors in immuno-oncology," Nature Reviews Drug Discovery, 2019.
- Choi, et al. "Patent landscapes for kinase inhibitors," Bioinformatics and Patent Analysis, 2020.
Disclaimer: This analysis is based on publicly available patent documents and literature as of the knowledge cutoff date in 2023. For legal or commercial decisions, consulting a patent attorney or expert is recommended.
More… ↓
⤷ Start Trial
|
